Kidney Cancer Cryoablation Highly Effective, Safe
The five-year cancer-specific and overall survival rates were 100% and 97.8%, respectively.
Computed tomography (CT)-guided percutaneous cryoablation for early-stage renal cell carcinoma (RCC) is highly efficacious and has a favorable safety profile, researchers reported online ahead of print in Cardiovascular and Interventional Radiology.
Christos S. Georgiades, MD, of the American Medical Center in Nicosia, Cyprus, and Ron Rodriguez, MD, of the University of Texas Health Science Center in San Antonio, treated 134 patients with biopsy-proven RCC using CT-guided cryotherapy. The median tumor size was 2.8 cm. The five-year cancer-specific and overall survival was 100% and 97.8%, respectively. No patient experienced metastatic disease during follow-up.
The technical objective was for the ice ball to cover the lesion plus a 5 mm margin. The most frequent complication—occurring in 1.6% of cases—was hemorrhage requiring a transfusion.